Reports

225 Results (Page 2 of 9)

Australia Markets Research Reports

Pharmaceuticals

Australia Cancer Immunotherapy Market Analysis

Australia's cancer immunotherapy market is expected to grow from $1.35 Bn in 2022 to $2.61 Bn in 2030 with a CAGR of 8.6% for the forecasted year 2022-30. The rising incidence of cancer cases and supportive government programs to promote cancer immunotherapy in Australia are responsible for the growth of the market. The Australian cancer immunotherapy market is segmented by type, application, and end user. Bioarc, Pharmaxis, and Bristol-Myers Squibb are the major players in the Australian cancer immunotherapy market.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Sep, 2023 | PRICE: $3999

Pharmaceuticals

Australia Antibacterial (Antibiotics) Drugs Market Analysis

This report presents a strategic analysis of the Australia Antibacterial (Antibiotics) Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Australian antibacterial (Antibiotics) Drugs Market, offering unmatched value, accuracy, and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Sep, 2023 | PRICE: $3999

Pharmaceuticals

Australia Anemia Drugs Market Analysis

Australia's Anemia drugs market was valued at $192 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 10.4% from 2022 to 2030 and will reach $423 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and awareness among people in Australia. The market is segmented by type, drug, and distribution channel. Some key players in this market are Pfizer, Roche, Sanofi, Novartis, Merck, Novo Nordisk, Otsuka, and Baxter among others.

PUBLISHED: Mar, 2023 | FORMAT: PPT | LAST UPDATED: Sep, 2023 | PRICE: $3999

Pharmaceuticals

Australia Oral Care Market Analysis

Australia's oral care market was valued at $423 Mn in 2022 and is estimated to expand at a CAGR of 7.7% from 2022 to 2030 and will reach $765 Mn in 2030. One of the main reasons propelling the growth of this market is increasing disposable income and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are White Glo, Grants of Australia, Red Seal, Dr. Brite, and Pure Smile

PUBLISHED: Mar, 2023 | FORMAT: PPT | LAST UPDATED: Aug, 2023 | PRICE: $3999

Pharmaceuticals

Australia Alzheimer’s Disease Drug Market Analysis

Australia's alzheimer’s disease drug market is expected to grow from $174.09K in 2022 to $222.94K in 2030 with a CAGR of 2.8% for the year 2022-30. Rising Alzheimer’s cases in Australia and increased investments by the government in the development of diagnostics and treatment modalities for Alzheimer’s disease in Australia are major market drivers of the Australia alzheimer’s disease drug market. The market is segmented by product, by drugs, and by distribution channel. Xenexus Pharmaceutical, Mediland Pharm, and Merz Pharma are some of the key players in this market.

PUBLISHED: Mar, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999 $2999

Pharmaceuticals

Australia Sickle Cell Disease Drug Market Analysis

Australia's Sickle Cell Disease Drug Market is expected to grow from $1.1 Mn in 2022 to $2.6 Mn in 2030 with a CAGR of 11% for the year 2022-2030. Immigration from other countries such as Africa and the Middle East etc along with newly licensed drugs for the treatment of sickle cell disease is driving the growth of the Australia Sickle Cell Disease Drug Market. the market is segmented by treatment modalities and by distribution channel. Some of the key players in the Australia Sickle Cell Disease Drug Market are Baxter Healthcare, Lipa Pharmaceutical, and Pfizer.

PUBLISHED: Mar, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999 $2999

Digital Health

Australia Telemedicine Market Analysis

Telemedicine is a sector of immense growth potential with a market size of about $730 Mn in 2022 with a CAGR of about 19.7% and is expected to grow to $3,075 Mn in 2030 as predicted by Insights10 report on the Australia Telemedicine Market Analysis. The inclusion of telemedicine services by general practitioners and telemedicine coverage in Medicare Australia are major growth drivers. The market is segmented by component, modality, application, and end user. Doxy.me Inc. and Teladoc Health are major market players in telemedicine.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Leukocyte Adhesion Deficiency (LAD-I) Market Analysis

Australia Leukocyte Adhesion Deficiency (LAD-I) therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. An uncommon genetic condition called leukocyte adhesion deficiency (LAD-I) impairs the immune system's capacity to combat infections. There is currently no cure for LAD-I, and there are few effective treatments available. To fill this unmet medical need, new medicines are becoming more and more popular. Vertex Pharmaceuticals, Orpha Labs, Avalo Therapeutics, Inc., Rocket Pharmaceuticals, Inc., Aspen Neuroscience, Magenta Therapeutics, Rubius Therapeutics, Enochian Biosciences, Sana Biotechnology, and Sigma-Aldrich are major global players.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Lysosomal Storage Disorders Drugs Market Analysis

Australia Lysosomal Storage Disease Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The rise in lysosomal diseases, greater public awareness of unusual lysosomal storage disorders, increased research and development for diagnostics, and increased drug development for treating lysosomal diseases are the main drivers impacting the market for lysosomal storage disease treatments. Major global players in Lysosomal Storage Disease Drugs Market are Pfizer Inc, Takeda Pharmaceutical Company Limited (Shire Plc), Sanofi (Genzyme Corporation), BioMarin, Johnson & Johnson (Actelion Pharmaceuticals Ltd), Amicus Drugs, Inc, Alexion Pharmaceuticals, Inc, Sigilon Drugs, Inc, and Orphazyme A/S are some of the companies that participate in this industry.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Morquio Syndrome (MPS-IV) Drugs Market Analysis

Australia Morquio Syndrome (MPS-IV) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. As genetic illnesses like Morquio Syndrome (MPS-IV) has become more common, there is an increasing demand for specialised drugs to treat them. Unmet clinical demands and improved treatment outcomes, Orphan Drug Designation and Incentives, Patient Advocacy and Support programmes. Major global players in Morquio Syndrome (MPS-IV) Drugs Market are BioMarin, Genzyme Corporation, Shire, JCR Pharmaceuticals Co., Ltd., Sanofi, Sangamo Drugs, ArmaGen and GREEN CROSS CORP, Concert Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., and other players.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia MPS-III (Sanfilippo Syndrome) Drugs Market Analysis

Australia MPS-III (Sanfilippo Syndrome) drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for MPS-III (Sanfilippo Syndrome) drugs is growing rapidly as a result of increase in research and development activities, patient support and advocacy programmes, launch of new emerging therapies, increase in healthcare spending globally. Phoenix Nest Inc, Allievex Corp, Amicus Therapeutics Inc, ArmaGen Inc, Esteve Pharmaceuticals SA, JCR Pharmaceuticals Co Ltd, M6P Therapeutics, Orchard Therapeutics Plc, Seelos Therapeutics, Inc., and BioStrategies LC are top key players operating in global MPS-III (Sanfilippo Syndrome) drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Mucopolysaccharidosis I (MPS-I) Drugs Market Analysis

Australia Mucopolysaccharidosis I (MPS-I) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Rising consumer awareness, new drug approvals, enticing reimbursement plans, an established healthcare system, and the presence of sizable market competitors all drive the market for treating Mucopolysaccharidosis I. Major global players in Mucopolysaccharidosis I (MPS-I) Drugs Market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Drugs, Abeona Drugs, Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Drugs, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Multiple Sclerosis Drugs Market Analysis

Australia Multiple Sclerosis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Multiple sclerosis is rising due to increase in Incidence and prevalence of multiple sclerosis (MS), Improved diagnosis and awareness, advancements in healthcare infrastructure , Advancements in Treatment Options, Expanding Pipeline of Innovative Therapies, technological advancements and increase in funding for research of multiple sclerosis. Major global players in Multiple Sclerosis Drugs Market are Abbott (U.S.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Takeda Pharmaceutical Company Limited (Japan), Jazz Pharmaceuticals, Inc. (U.K.), Novartis AG (Switzerland), Biora Therapeutics, Inc. (U.S.), Bausch Health Companies Inc. (Canada), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Mylan N.V. (U.S.)

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Myasthenia Gravis Drugs Market Analysis

Australia Myasthenia Gravis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for myasthenia gravis is rising due to increasing prevalence and incidence of disease, improved diagnostic techniques, increased awareness and better understanding of the disease, Supportive Government Initiatives like providing financial support, improving healthcare infrastructure, promoting research in rare diseases and Technological Advancements in drugs and therapies treating myasthenia gravis. Major global players in Myasthenia Gravis Drugs Market are Alexion Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Avadel, Dr. Reddy's Laboratories, Ltd., Fresenius Kabi, AG, Endo Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc., Mylan N.V., Aurobindo Pharma, Pfizer, Inc., Astellas Pharma, Inc.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market Analysis

Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Increasing awareness and diagnosis, Increasing funding for medical infrastructure and high rate of multiple sclerosis prevalence (MS), unmet medical needs, advancements in drug development, Regulatory Approvals of drugs like eculizumab, inebilizumab and satralizumab , rising healthcare expenditure and growing collaborations in research and development of drugs are the major drivers for Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs Market. Major global players in Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics PLC (Ireland), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark).

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Oculopharyngeal Muscular Dystrophy (OPMD) Market Analysis

Australia Oculopharyngeal Muscular Dystrophy (OPMD) market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Oculopharyngeal Muscular Dystrophy (OPMD)is growing due to increase spending in research and development activities by pharmaceutical companies, incentives provided by regulatory authorities like orphan drug designations and accelerated approval pathways, patient support and advocacy programmes which help to increase awareness about disease and provide support to patients. Bristol-Myers Squibb, BioMarin, Sarepta Therapeutics, Benitec Biopharma Inc., Bioblast Pharma, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd ,Santhera Pharmaceuticals, Pfizer Inc. ,Marathon Pharmaceuticals, Fibrogen, GSK are the key global market players.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia POMC Genetic Obesity Drugs Market Analysis

Australia POMC Genetic Obesity Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for POMC Genetic Obesity Drugs is growing due to increase spending in research and development activities by pharmaceutical companies, introduction of new emerging therapies like gene editing and gene replacement approaches, incentives provided by regulatory body?s in the form of orphan drug designations. Novo Nordisk A/S , rhythm Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated ,Amgen Inc are the key market players operating in global POMC genetic obesity drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Pompe Disease Drugs Market Analysis

Australia Pompe Disease Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Pompe disease Drugs is growing due to increase in awareness about the disease , better diagnosis, advancements in treatment options and increase in research and development activities by different pharmaceutical companies and research organizations. Sanofi Genzyme ,BioMarin Pharmaceutical Inc., Avrobio Inc., Amicus Therapeutics Inc. are the key market players operating in global pompe disease market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Primary Hyperoxaluria (PH) Drugs Market Analysis

Australia Primary Hyperoxaluria (PH) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Unmet Medical Need, Increasing Awareness and Diagnosis, Advancements in Research and Development, Growing Investment and Pipeline Development, Collaboration and Patient Advocacy,rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Drugs Market are Allena Pharmaceuticals, Inc., Intellia Drugs, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Pyruvate Kinase (PK) Deficiency Market Analysis

Australia Pyruvate Kinase (PK) deficiency market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Pyruvate Kinase (PK) deficiency is growing rapidly as a result of increase in incidence and prevalence of disease, increased awareness about the disease, improved diagnostic techniques, advancements in treatment options, increase in research and development and rise in patient assistance programmes. Agios pharmaceuticals, Pfizer Inc., Sanofi, Novartis, Teva Pharmaceutical Industries Ltd, Green cross corporation are the top key market players operating in the global Pyruvate Kinase (PK) deficiency market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Rare Hematology Disorders Market Analysis

Australia Rare Hematology Disorders market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Rare Hematology Disorders is growing rapidly as a result of increase in incidence of rare blood disorders, increase in awareness of rare hematology disorders, advancement in genetic testing and diagnostic techniques, increase in spending on healthcare infrastructure and increasing adoption of gene therapy. Sanofi Genzyme, Pfizer Inc., Novartis AG, Alexion Pharmaceuticals, Shire., BioMarin Pharmaceutical Inc., CSL Behring are the key global market players operating in rare hematology disorders market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Rare Hemophilia Factors Market Analysis

Australia Rare Hemophilia Factors market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Rare Hemophilia Factors is growing rapidly as a result of growing incidence of rare hemophilia factors deficiency, rising adoption of prophylactic treatments, growing awareness about rare hemophilia factors and their treatment options, rising demand for better and more effective therapies for rare hemophilia factors. Baxter, Bayer AG, Bio Products Laboratory Ltd., Novo Nordisk A/S, Alexion Pharmaceuticals, Amgen Inc, BioMarin, Amgen Inc are the key global market players operating in rare hemophilia factors market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Rett Syndrome Drugs Market Analysis

Australia Rett Syndrome Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Rett syndrome will grow over time as a result of expanding female population, rising public healthcare programme spending for patient advocacy and rising global healthcare expenditure. Major global players in Rett Syndrome Drugs Market are Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (U.K.), Sanofi (France), Novartis AG (Switzerland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (U.S.), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India)

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Sickle Cell Disease Drugs Market Analysis

Australia Sickle cell disease Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Sickle cell disease Drugs is growing rapidly as a result of increasing prevalence of sickle cell disease , increasing investment for healthcare infrastructure, increase in the number of research and development activities, Support provided by governments of different countries, patient advocacy programmes and incentives provided by regulatory authorities. Global Blood Therapeutics, Novartis, Emmaus Life Sciences, Bluebird Bio, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Mylan N.V., Merck & Co., Inc., Johnson & Johnson Private Limited, Bristol-Myers Squibb Company, AbbVie Inc are the key global market players operating in sickle cell disease Drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Soft Tissue Sarcoma Market Analysis

Australia Soft Tissue Sarcoma market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Soft Tissue Sarcoma is growing rapidly as a result of increasing prevalence and incidence of soft tissue sarcoma, rising awareness about the disease, rising research and development activities on drugs and other therapies, increase in partnerships between pharmaceutical companies for drug development and advancements in diagnostics. Pfizer Inc, Eli Lilly and Company, Johnson & Johnson, Bayer AG, Eisai Co., Ltd., Epizyme, Inc., Adaptimmune Therapeutics, Mylan N.V., Sanofi are the key market players operating in global Soft Tissue Sarcoma market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

subscribe to our newsletter
up